Clinical Study

Optune Lua For Malignant Pleural Mesothelioma

Posted Date: Feb 25, 2022

  • Investigator: Emily Daugherty
  • Specialties: Cancer, Lung Cancer, Oncology, Pulmonary Diseases, Radiation Oncology
  • Type of Study: Device

Certified user delivery of Optune Lua for use concurrent with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic malignant pleural mesothelioma (MPM).


Patients Over 18 Years Old With Unresectable, Locally Advanced Or Metastatic Malignant Pleural Mesothelioma (Mpm)


Tumor-Treating Fields, Mesothelioma

For More Information:

Dr. Emily Daugherty, Md

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.